Active ingredientCilazaprilCat. No. P-C161-001CAS 88768-40-5Family · Pharmaceutical analytical standards
Cilazapril
An ACE inhibitor used for high blood pressure and heart failure, patented in 1982 and approved for medical use in 1990. Of the eight possible stereoisomeric forms of the molecule, only one, the all-(S) form, is suitable as a medicine. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.
Did you know?Its core is an uncommon two-ring system, a pyridazino-diazepine: a six-membered ring fused to a seven-membered one, each containing two nitrogen atoms.
Go to the active ingredient →Active ingredientCilazaprilCat. No. P-C161-001CAS 88768-40-5
Active ingredientCilazapril MonohydrateCat. No. P-C161-002CAS 92077-78-6
Pharmacopoeial impurityCilazapril EP Impurity ACat. No. P-C161-003CAS 106860-19-9
Pharmacopoeial impurityCilazapril EP Impurity BCat. No. P-C161-004CAS 90139-06-3
Pharmacopoeial impurityCilazapril EP Impurity DCat. No. P-C161-005CAS 106928-09-0
Pharmacopoeial impurityent-Cilazapril EP Impurity DCat. No. P-C161-006
Isotopically labelledCilazapril-d5Cat. No. P-C161-007
NitrosamineN-Nitroso CilazaprilCat. No. P-C161-008CAS 1053740-92-3
NitrosamineN-Nitroso Cilazapril EP Impurity ACat. No. P-C161-009
Impurity(R,S,R)-CilazaprilCat. No. P-C161-010
Impurity(R,S,S)-CilazaprilCat. No. P-C161-011CAS 106928-07-8
Impurity(S,R,R)-CilazaprilCat. No. P-C161-012
Impurity(S,R,S)-CilazaprilCat. No. P-C161-013CAS 106928-08-9
Impurityent-CilazaprilCat. No. P-C161-014No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Reference substanceCilazapril CRSEDQM code C2174000Family CilazaprilImpurityCilazapril impurity A CRSEDQM code C2174002Family CilazaprilImpurityCilazapril impurity D CRSEDQM code C2174005Family CilazaprilNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.